Full Text Journal Articles by
Author Dimos Mitsikostas

Advertisement

Find full text journal articles






Tension-type headache.

Sait Ashina, Dimos D Mitsikostas, Mi Ji Lee, Nooshin Yamani, Shuu-Jiun Wang, Roberta Messina, Håkan Ashina, Dawn C Buse, Patricia Pozo-Rosich, Rigmor H Jensen, Hans-Christoph Diener, Richard B Lipton,

Tension-type headache (TTH) is the most prevalent neurological disorder worldwide and is characterized by recurrent headaches of mild to moderate intensity, bilateral location, pressing or tightening quality, and no aggravation by routine physical activity. Diagnosis is based on headache history and the exclusion of alternative diagnoses, with clinical criteria provided ... Read more >>

Nat Rev Dis Primers (Nature reviews. Disease primers)
[2021, 7(1):24]

Cited: 0 times

View full text PDF listing >>



The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions.

Panagiotis Gklinos, Dimos D Mitsikostas,

Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in reducing migraine headaches, migraine-specific quality of life, and headache-related disability. Most of the adverse events (AEs) were ... Read more >>

Pharmaceuticals (Basel) (Pharmaceuticals (Basel, Switzerland))
[2021, 14(3):]

Cited: 0 times

View full text PDF listing >>



Advertisement

Migraine: integrated approaches to clinical management and emerging treatments.

Messoud Ashina, Dawn C Buse, Håkan Ashina, Patricia Pozo-Rosich, Mario F P Peres, Mi Ji Lee, Gisela M Terwindt, Rashmi Halker Singh, Cristina Tassorelli, Thien Phu Do, Dimos D Mitsikostas, David W Dodick,

Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. ... Read more >>

Lancet (Lancet (London, England))
[2021, :]

Cited: 0 times

View full text PDF listing >>



A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.

Dimos D Mitsikostas, Triantafyllos Doskas, Stylianos Gkatzonis, Nikolaos Fakas, Maria Maltezou, Dimitrios Papadopoulos, Rania Gourgioti, Panayiotis Mitsias,

<h4>Introduction</h4>The efficacy of prolonged-release fampridine (PR-FAM) may extend in multiple sclerosis (MS) beyond walking ability. The objective of this study was to evaluate the effect of PR-FAM treatment on cognition, fatigue, depression, and quality of life (QoL) in adult patients with MS in a real-world setting.<h4>Methods</h4>FAMILY was a multi-center, prospective, ... Read more >>

Adv Ther (Advances in therapy)
[2021, 38(3):1536-1551]

Cited: 0 times

View full text PDF listing >>



Making headway - a role for CGRP in post-traumatic headache.

Dimos D Mitsikostas, Michael A Moskowitz,

Nat Rev Neurol (Nature reviews. Neurology)
[2021, 17(3):133-134]

Cited: 0 times

View full text PDF listing >>



Monoclonal Antibodies as Neurological Therapeutics.

Panagiotis Gklinos, Miranta Papadopoulou, Vid Stanulovic, Dimos D Mitsikostas, Dimitrios Papadopoulos,

Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of ... Read more >>

Pharmaceuticals (Basel) (Pharmaceuticals (Basel, Switzerland))
[2021, 14(2):]

Cited: 0 times

View full text PDF listing >>



Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.

Konstantina Drellia, Lili Kokoti, Christina I Deligianni, Dimitrios Papadopoulos, Dimos D Mitsikostas,

<h4>Introduction and objective</h4>Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical trials for the prevention of episodic and chronic migraine, but no head-to-head comparisons with established treatments are available. We aimed to examine absolute differences in benefit-risk ratios between anti-CGRP mAbs, topiramate ... Read more >>

Cephalalgia (Cephalalgia : an international journal of headache)
[2021, :333102421989601]

Cited: 1 time

View full text PDF listing >>



A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.

Theodoros S Constantinidis, Chryssa Arvaniti, Nikolaos Fakas, Jobst Rudolf, Evangelos Kouremenos, Ermioni Giannouli, Dimos D Mitsikostas,

<h4>Objective</h4>To estimate the prevalence, burden and current treatment of disabling primary headaches in a large sample of the Greek population aged 18-70 years old.<h4>Methods</h4>This is an observational descriptive study, with cross-sectional design performed by quantitative computer-assisted telephone interviews, using a validated 37-item questionnaire for headaches. The prevalence, burden, and current ... Read more >>

Cephalalgia (Cephalalgia : an international journal of headache)
[2021, :333102421989630]

Cited: 0 times

View full text PDF listing >>



Diarrhoea in Systemic Sclerosis Patients as a Nocebo Effect of Nintedanib.

Vasiliki-Kalliopi Bournia, Oliver Distler, Evrydiki Kravvariti, Dimos Mitsikostas, Petros P Sfikakis,

Eur Respir J (The European respiratory journal)
[2020, :]

Cited: 0 times

View full text PDF listing >>



352. Seronegative Relapse of Brucellosis in the Central Nervous System

Vassilis E Papadopoulos, Argyro Tountopoulou, Kostas Patas, Aegli Vakrakou, Eleftheria Koropouli, Sophia Vassilopoulou, Dimos Mitsikostas,

Abstract <h4>Background</h4> Brucellosis is the most common zoonotic infection in the world. High risk areas include the Mediterranean Basin, Eastern Europe and the Middle East. Clinical presentation is quite heterogenous. CNS involvement (neurobrucellosis) varies widely, from 0,5 to 25%. This reflects a high prevalence in endemic areas and the lack ... Read more >>

Open Forum Infect Dis (Open forum infectious diseases)
[2020, 7(Suppl 1):S245-S245]

Cited: 0 times

View full text PDF listing >>



European Headache Federation recommendations for placebo and nocebo terminology.

Dimos D Mitsikostas, Charlotte Blease, Elisa Carlino, Luana Colloca, Andrew L Geers, Jeremy Howick, Andrea W M Evers, Magne A Flaten, John M Kelley, Irving Kirsch, Regine Klinger, Antoinette MaassenVanDenBrink, Daniel E Moerman, Petros P Sfikakis, Lene Vase, Tor D Wager, Fabrizio Benedetti, ,

<h4>Background and aim</h4>Despite recent publications, practitioners remain unfamiliar with the current terminology related to the placebo and nocebo phenomena observed in clinical trials and practice, nor with the factors that modulate them. To cover the gap, the European Headache Federation appointed a panel of experts to clarify the terms associated ... Read more >>

J Headache Pain (The journal of headache and pain)
[2020, 21(1):117]

Cited: 1 time

View full text PDF listing >>



Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic.

George E Fragoulis, Gerasimos Evangelatos, Aikaterini Arida, Vasiliki-Kalliopi Bournia, Kalliopi Fragiadaki, Anastasios Karamanakos, Evrydiki Kravvariti, Katerina Laskari, Stylianos Panopoulos, Maria Pappa, Dimos D Mitsikostas, Maria G Tektonidou, Petros P Sfikakis,

<h4>Background</h4>The COVID-19 pandemic is associated with emotional distress and significant disruptions in health-care services. These are key players in the development of nocebo phenomena. We aimed to investigate nocebo-prone behaviour in patients with autoimmune rheumatic diseases (ARD) amid the COVID-19 pandemic-associated lockdown.<h4>Methods</h4>Consecutive patients were telephone-interviewed during the COVID-19 pandemic in ... Read more >>

Mediterr J Rheumatol (Mediterranean journal of rheumatology)
[2020, 31(Suppl 2):288-294]

Cited: 0 times

View full text PDF listing >>



IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.

Dimos D Mitsikostas, Andrzej Dekundy, Kati Sternberg, Michael Althaus, Fernando Pagan,

This study aimed to assess the efficacy/safety of incobotulinumtoxinA (Xeomin<sup>®</sup>, Merz Pharmaceuticals GmbH) in botulinum neurotoxin-naïve subjects with blepharospasm. Botulinum neurotoxin-naïve subjects (≥ 12 months without botulinum neurotoxin treatment for blepharospasm) received single-dose incobotulinumtoxinA 50 U, 25 U, or placebo. Subjects were followed for 6-20 weeks (main period). Qualified subjects entered an open-label extension ... Read more >>

Adv Ther (Advances in therapy)
[2020, 37(10):4249-4265]

Cited: 1 time

View full text PDF listing >>



Aging, Cellular Senescence, and Progressive Multiple Sclerosis.

Dimitrios Papadopoulos, Roberta Magliozzi, Dimos D Mitsikostas, Vassilis G Gorgoulis, Richard S Nicholas,

Aging is one of the most important risk factors for the development of several neurodegenerative diseases including progressive multiple sclerosis (MS). Cellular senescence (CS) is a key biological process underlying aging. Several stressors associated with aging and MS pathology, such as oxidative stress, mitochondrial dysfunction, cytokines and replicative exhaustion are ... Read more >>

Front Cell Neurosci (Frontiers in cellular neuroscience)
[2020, 14:178]

Cited: 1 time

View full text PDF listing >>



Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.

Brian Steingo, Yaser Al Malik, Ann D Bass, Regina Berkovich, Matthew Carraro, Óscar Fernández, Carolina Ionete, Luca Massacesi, Sven G Meuth, Dimos D Mitsikostas, Gabriel Pardo, Renata Faria Simm, Anthony Traboulsee, Zia Choudhry, Nadia Daizadeh, D Alastair S Compston, ,

<h4>Background</h4>In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing-remitting MS. Here, we assess efficacy and safety of alemtuzumab over 12 years in CAMMS223 patients who enrolled in the CAMMS03409 extension (NCT00930553), with available follow-up through ... Read more >>

J Neurol (Journal of neurology)
[2020, 267(11):3343-3353]

Cited: 0 times

View full text PDF listing >>



Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.

Antonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D Mitsikostas, Barry A Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior,

<h4>Introduction</h4>In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (RRMS).<h4>Methods</h4>In phase 3 CARE-MS I (NCT00530348) and II (NCT00548405) trials, patients with RRMS were administered alemtuzumab 12 mg/day on ... Read more >>

Neurol Ther (Neurology and therapy)
[2020, 9(2):443-457]

Cited: 1 time

View full text PDF listing >>



Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis.

George Markousis-Mavrogenis, Michael T Nurmohamed, Loukia Koutsogeorgopoulou, Theodoros Dimitroulas, Gikas Katsifis, Vasiliki Vartela, Dimos Mitsikostas, Genovefa Kolovou, Maria Tektonidou, Paraskevi Voulgari, Petros P Sfikakis, George D Kitas, Sophie I Mavrogeni,

Psoriatic arthritis (PsA) patients are at a higher risk of systemic inflammatory sequelae, leading to microalbuminuria, cardiovascular (CVD) and neuropsychiatric (NPD) disease. Our aim is to present the existing literature about the relationship between CVD, kidney and NPD in PsA. The literature evaluation of PsA revealed that chronic T-cell activation ... Read more >>

Rheumatol Int (Rheumatology international)
[2020, 40(9):1361-1368]

Cited: 0 times

View full text PDF listing >>



Is There a Brain/Heart Interaction in Rheumatoid Arthritis and Seronegative Spondyloartropathies? A Combined Brain/Heart Magnetic Resonance Imaging Reveals the Answer.

George Markousis-Mavrogenis, Loukia Koutsogeorgopoulou, Theodoros Dimitroulas, Gikas Katsifis, Vasiliki Vartela, Dimos Mitsikostas, Genovefa Kolovou, Paraskevi Voulgari, Petros P Sfikakis, George D Kitas, Sophie I Mavrogeni,

<h4>Purpose of review</h4>To present the interaction between brain/heart and emphasize the role of combined brain/heart magnetic resonance imaging (MRI) in patients with rheumatoid arthritis (RA) and other seronegative spondyloarthropathies (SNA).<h4>Recent findings</h4>Both traditional cardiovascular disease (CVD) risk factors and intrinsic RA/SNA features contribute to the increased CVD-related morbidity/mortality. CVD in RA ... Read more >>

Curr Rheumatol Rep (Current rheumatology reports)
[2020, 22(8):39]

Cited: 0 times

View full text PDF listing >>



Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

Panagiotis Gklinos, Dimos D Mitsikostas,

Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To provide a pooled safety and efficacy analysis of all phase III randomized controlled ... Read more >>

Ther Adv Neurol Disord (Therapeutic advances in neurological disorders)
[2020, 13:1756286420918088]

Cited: 2 times

View full text PDF listing >>



Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-sectional Study.

George Markousis-Mavrogenis, Dimos D Mitsikostas, Loukia Koutsogeorgopoulou, Theodoros Dimitroulas, Gikas Katsifis, Panayiotis Argyriou, Dimitrios Apostolou, Stella Velitsista, Vasiliki Vartela, Dionysia Manolopoulou, Maria G Tektonidou, Genovefa Kolovou, George D Kitas, Petros P Sfikakis, Sophie I Mavrogeni,

BACKGROUND:Autoimmune rheumatic diseases (ARDs) may affect both the heart and the brain. However, little is known about the interaction between these organs in ARD patients. We asked whether brain lesions are more frequent in ARD patients with cardiac symptoms compared with non-ARD patients with cardiovascular disease (CVD). METHODS:57 ARD patients ... Read more >>

J Clin Med (Journal of clinical medicine)
[2020, 9(2):]

Cited: 2 times

View full text PDF listing >>



Diagnostic and Therapeutic Errors in Classical Trigeminal Neuralgia: a Multicenter Survey

Fabio Antonaci, Sebastiano Arceri, Martin Rakusa, Dimos Mitsikostas, Ivan Milanov, Vasil Todorov, Matteo Cotta Ramusino, Alfredo Costa,

<h4>Background: </h4> Classical Trigeminal neuralgia (CTN) is a severe, disabling form of painful cranial neuropathy. Even though CTN has a typical clinical picture, diagnosis it is often missed or delayed in clinical practice. This study was carried over to investigate the occurrence of diagnostic and therapeutic errors in CNT. Methods ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.

Lili Kokoti, Konstantina Drellia, Dimitrios Papadopoulos, Dimos D Mitsikostas,

High placebo and low nocebo phenomena mirror high positive expectations for a novel treatment, among other reasons. In a meta-analysis aimed to identify placebo and nocebo phenomena in the placebo-controlled randomized trials (RCTs) with the monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) all the placebo-treated patients were ... Read more >>

J Neurol (Journal of neurology)
[2020, 267(4):1158-1170]

Cited: 2 times

View full text PDF listing >>



Editorial: Nocebo Effects and Their Influence on Clinical Trials and Practice: Modulating Factors in Healthy and Pathological Conditions.

Martina Amanzio, Lene Vase, Dimos D Mitsikostas,

Front Pharmacol (Frontiers in pharmacology)
[2020, 11:100]

Cited: 2 times

View full text PDF listing >>



Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.

Evangelos Kouremenos, Chrysa Arvaniti, Theodoros S Constantinidis, Ermioni Giannouli, Nikolaos Fakas, Themistoklis Kalamatas, Evangelia Kararizou, Dimitrios Naoumis, Dimos D Mitsikostas, ,

More than 0.6 million people suffer from disabling migraines in Greece causing a dramatic work loss, but only a small proportion of migraineurs attend headache centres, most of them being treated by non-experts. On behalf of the Hellenic Headache Society, we report here a consensus on the diagnosis and treatment ... Read more >>

J Headache Pain (The journal of headache and pain)
[2019, 20(1):113]

Cited: 2 times

View full text PDF listing >>



Lateralization of Insular Ischemic Stroke is Not Associated With Any Stroke Clinical Outcomes: The Athens Stroke Registry.

Sophia Vassilopoulou, Eleni Korompoki, Argyro Tountopoulou, Dimos D Mitsikostas, Efstathios Manios, Georgios Georgiopoulos, George Ntaios, Haralampos Milionis, Sophia Fontara, Konstantinos Vemmos,

BACKGROUND:Controversial evidence suggests that right insular stroke may be associated with worse outcomes compared to the left insular ischemic lesion. OBJECTIVES:We investigated whether lateralization of insular stroke is associated with early and late outcome in terms of in-hospital complications, stroke recurrence, cardiovascular events, and death. METHODS:Data were prospectively collected from ... Read more >>

J Stroke Cerebrovasc Dis (Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association)
[2020, 29(2):104529]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.98 s